Interferon-α2B promising for idiopathic hypereosinophilic syndrome
1
14 THER\PY Interferon-a2B promising for idiopathic bypereosinophilic syndrome SC interferon-alB 1-8 MU/day resulted in improvements in 5/6 patients with refractory idiopathic hypereosinophilic syndrome. report investigators from the Mayo Clinic. Rochester. US. Four patients had cardiac and CNS involvement. 4 had splenomegaly and 2 had mucosal ulcers. Peripheral blood counts were measured daily before and after dosage increases. then every 3 to 4 weeks thereafter. Bone marrow eosinophil counts were performed before and after each patient completed at least 9 months' treatment. The goal was to achieve a decrease in total eosinophil count of 90% or to fewer than 1000 cells/mm 3 . During interferon-alB therapy. 5 of 6 patients achieved their goal eosinophil count. These patients were able to discontinue glucocorticoid or cytotoxic medications and transfusions during treatment. One patient died. The patients' bone marrow eosinophil counts decreased by up to 80%. compared with baseline. Buttt:rfieid IH. Gleicb GJ. treaIlDC:nl of six patients with the idiopalhic hyp:rrosir.ophilic syndrome. Annals of Intar.al Medicine 121: 648-653, 1 Nov 1994 '00""'" 26 Nov'''' INPHARMA- 0156-2703l94I0965-000141$01.000 Ad'- International Limited , .... All rights -...cI
Transcript of Interferon-α2B promising for idiopathic hypereosinophilic syndrome
14 THER\PY
Interferon-a2B promising for idiopathic bypereosinophilic syndrome
SC interferon-alB 1-8 MU/day resulted in improvements in 5/6 patients with refractory idiopathic hypereosinophilic syndrome. report investigators from the Mayo Clinic. Rochester. US.
Four patients had cardiac and CNS involvement. 4 had splenomegaly and 2 had mucosal ulcers. Peripheral blood counts were measured daily before and after dosage increases. then every 3 to 4 weeks thereafter. Bone marrow eosinophil counts were performed before and after each patient completed at least 9 months' treatment. The goal was to achieve a decrease in total eosinophil count of ~ 90% or to fewer than 1000 cells/mm3.
During interferon-alB therapy. 5 of 6 patients achieved their goal eosinophil count. These patients were able to discontinue glucocorticoid or cytotoxic medications and transfusions during treatment. One patient died.
The patients' bone marrow eosinophil counts decreased by up to 80%. compared with baseline. Buttt:rfieid IH. Gleicb GJ. In~cron-alpha treaIlDC:nl of six patients with the idiopalhic hyp:rrosir.ophilic syndrome. Annals of Intar.al Medicine 121:
648-653, 1 Nov 1994 '00""'"
26 Nov'''' INPHARMA- 0156-2703l94I0965-000141$01.000 Ad'- International Limited , .... All rights -...cI
![Clinical Characteristics to Differentiate · Asthma-COPD overlap syndrome (ACOS) [a description] Asthma-COPD overlap syndrome (ACOS) is characterized by persistent airflow limitation](https://static.fdocument.org/doc/165x107/5f0914d17e708231d4252460/clinical-characteristics-to-differentiate-asthma-copd-overlap-syndrome-acos-a.jpg)
